Adriano V.
- Country
- Italy
- Department
- Hematology
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase 3 Randomized Trial of Cytarabine, Midostaurin, and Daunorubicin Hydrochloride in FLT3-Mutated Acute Myeloid Leukemia with Peripheral Blast Clearance
- Evaluation of RVU120 Monotherapy in Relapsed/Refractory High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with/without NPM1 Mutation
Data & Insights
Has run more than one trial at 226 of 356 partner sites.
Specializations
Acute Myeloid Leukemia Research
The investigator specializes in studying various forms of acute myeloid leukemia (AML), with particular emphasis on genetic mutations and treatment resistance patterns.
- NPM1-mutated AML
- FLT3-positive AML
- IDH1-mutated AML
Primary focus includes investigating novel therapeutic approaches for both newly diagnosed and relapsed/refractory AML cases.
Therapeutic Innovations
Active research in developing and evaluating innovative treatment combinations for hematologic malignancies, particularly focusing on targeted therapies and novel drug combinations.
- Menin-MLL inhibitor studies
- Venetoclax combinations
- Biomarker-driven therapies
Specializes in determining optimal treatment strategies for patients unsuitable for intensive chemotherapy.
Treatment Resistance Studies
Conducts research on treatment-resistant leukemia and investigates solutions for patients who have failed conventional therapies.
- Minimal residual disease monitoring
- Second-line treatment strategies
- Novel therapeutic combinations
Explores innovative approaches for overcoming drug resistance in hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.